Predominant genotypes of human papillomavirus in Korean men

Human papillomavirus (HPV) is associated with several types of cancers in men, including head and neck, anal and genital cancers. However, research on HPV has primarily focused on women, and available data from men are limited. This study aimed to evaluate the positivity rate, genotype distribution, and co-infection rates of HPV in Korean men who visited a hospital owing to a suspected sexually transmitted infection. A total of 14,994 samples sent to specialized laboratories between January 2020 and June 2023 were included in this study. HPV genotypes were determined in the collected specimens (including swabs and urine, semen and prostatic fluid samples). The HPV genotypes varied with age; single infections and co-infections with two or more genotypes were confirmed. A high positivity rate of HPV was observed among Korean men from their teens to their 70s. Single and co-infection positivity rates differed significantly among ages (χ2 = 81.502, p < 0.0001). The most frequently identified HPV genotypes were 6 and 11, whereas the positivity rate of the high-risk genotype 16 increased with age (χ2 = 1012.028, p < 0.0001). Sexual health management efforts should be directed toward both men and women to mitigate disease burden and transmission risks and prevent cervical cancer. A comprehensive analysis of HPV infections in men is warranted.

Cervical cancer; Genotype; Human papillomavirus; Male; Multiple infection

[1] World Health Organization. Global Cancer Observatory. Cancer Today. Estimated number of incident cases and deaths: world, both sexes, all ages 2020. 2020. Available at: https://gco.iarc.fr/today/home (Accessed: 22 December 2023).

[2] Centers for Disease Control and Prevention (CDC). STI prevalence, incidence, and cost estimates in the United States, 2018. 2021. Available at: https://www.cdc.gov/std/statistics/prevalence-2020-at-a-glance.htm (Accessed: 07 December 2023).

[3] Anic GM, Giuliano AR. Genital HPV infection and related lesions in men. Preventive Medicine. 2011; 53: S36–S41.

[4] Muscianisi F, De Toni L, Giorato G, Carosso A, Foresta C, Garolla A. Is HPV the novel target in male idiopathic infertility? A systematic review of the literature. Frontiers in Endocrinology. 2021; 12: 643539.

[5] McNicol PJ, Dodd JG. Detection of human papillomavirus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. Journal of Clinical Microbiology. 1990; 28: 409–412.

[6] Dibble KE, Maksut JL, Siembida EJ, Hutchison M, Bellizzi KM. A systematic literature review of HPV vaccination barriers among adolescent and young adult males. Journal of Adolescent and Young Adult Oncology. 2019; 8: 495–511.

[7] Han JJ, Beltran TH, Song JW, Klaric J, Choi YS. Prevalence of genital human papillomavirus infection and human papillomavirus vaccination rates among US adult men: national health and nutrition examination survey (NHANES) 2013–2014. JAMA Oncology. 2017; 3: 810–816.

[8] Tuominen H, Rautava J, Kero K, Syrjänen S, Collado MC, Rautava S. HPV infection and bacterial microbiota in the semen from healthy men. BMC Infectious Diseases. 2021; 21: 373.

[9] Ingles DJ, Lin H, Fulp WJ, Sudenga SL, Lu B, Schabath MB, et al. An analysis of HPV infection incidence and clearance by genotype and age in men: the HPV infection in men (HIM) Study. Papillomavirus Research. 2015; 1: 126–135.

[10] Magana K, Strand L, Love M, Moore T, Peña A, Ford AI, et al. Health inequities in human papillomavirus prevention, diagnostics and clinical care in the USA: a scoping review. Sexually Transmitted Infections. 2023; 99: 128–136.

[11] López ED. Vaccination against human papillomavirus (HPV) in vulnerable populations—sexual minorities. Molecular Mechanisms in Cancer. 1st edn. IntechOpen: London. 2022.

[12] Tsu VD, LaMontagne DS, Atuhebwe P, Bloem PN, Ndiaye C. National implementation of HPV vaccination programs in low-resource countries: lessons, challenges, and future prospects. Preventive Medicine. 2021; 144: 106335.

[13] Foresta C, Garolla A, Parisi S, Ghezzi M, Bertoldo A, Di Nisio A, et al. HPV prophylactic vaccination in males improves the clearance of semen infection. EBioMedicine. 2015; 2: 1487–1493.

[14] Ventimiglia E, Horenblas S, Muneer A, Salonia A. Human papillomavirus infection and vaccination in males. European Urology Focus. 2016; 2: 355–362.

[15] Rezaee Azhar I, Yaghoobi M, Mossalaeie MM, Kollaee Darabi A, Nejadeh AH, Jamshidi M, et al. Prevalence of human papillomavirus (HPV) genotypes between outpatients males and females referred to seven laboratories in Tehran, Iran. Infectious Agents and Cancer. 2022; 17: 7.

[16] Bruni L, Albero G, Rowley J, Alemany L, Arbyn M, Giuliano AR, et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis. The Lancet Global Health. 2023; 11: e1345–e1362.

[17] Sabet F, Mosavat A, Ahmadi Ghezeldasht S, Basharkhah S, Shamsian SAA, Abbasnia S, et al. Prevalence, genotypes and phylogenetic analysis of human papillomaviruses (HPV) in northeast Iran. International Journal of Infectious Diseases. 2021; 103: 480–488.

[18] Zou K, Huang Y, Li Z. Prevention and treatment of human papillomavirus in men benefits both men and women. Frontiers in Cellular and Infection Microbiology. 2022; 12: 1750.

[19] Rodríguez-Álvarez MI, Gómez-Urquiza JL, Husein-El Ahmed H, Albendín-García L, Gómez-Salgado J, Cañadas-De la Fuente GA. Prevalence and risk factors of human papillomavirus in male patients: a systematic review and meta-analysis. International Journal of Environmental Research and Public Health. 2018; 15: 2210.

[20] Hoai BN, Cao TN, Luong Thi LA, Nguyen MN, Duong HQ, Than VT. Human papillomavirus prevalence and genotype distribution in Vietnamese male patients between 2016 and 2020. Journal of Medical Virology. 2022; 94: 2892–2896.

[21] Goldstone SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, Penny ME, Cabello RE, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases. 2022; 22: 413–425.

[22] Gou T, Liu P, Yao X, Zhang L. Clinical characteristics of human papillomavirus infection in the male genital tract. Alternative Therapies in Health and Medicine. 2023; 29: 425–429.

[23] Hussain S, Rani J, Tulsyan S, Sisodiya S, Chikara A, Nazir SU, et al. Influence of HPV infection in esophageal cancer: a systematic review and meta-analysis. Gene Reports. 2022; 28: 101640.

[24] Jin H, Kim DH, Lee KE. Human papillomavirus prevalence in urine samples of asymptomatic male sexual partners of women with sexually transmitted diseases. International Journal of Environmental Research and Public Health. 2021; 18: 11706.

[25] Kim HW, Kim SE, Ahn HY, Lee EJ, Lee JL, Kang SY, et al. Association of the perceived severity of the human papillomavirus with the preventive intention of HPV infection in male adolescents: a cross-sectional survey. Journal of Men’s Health. 2019; 15: 47–57.

[26] Grewal R, Deeks SL, Hart TA, Cox J, De Pokomandy A, Grennan T, et al. HPV vaccination among gay, bisexual and other men who have sex with men in Canada’s three largest cities: a person-centred approach. Journal of Men’s Health. 2023; 19: 22–33.